Brain

Mentavi Health Offers Tips and Tools to Help Manage Stress During the Holiday Season

Nearly half of all Americans feel more pressure from time commitments, stretched finances, gift-giving, and family gatherings. Mentavi, a leader…

1 year ago

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric…

1 year ago

Darmiyan Enters Medicare GUIDE Program Through Partnership with Five Star Home Health Care, CareBrains, and Brain Watch Coalition

SAN FRANCISCO, Dec. 19, 2024 /PRNewswire/ -- Darmiyan, Inc., a leader in brain health technology, proudly announces its participation in…

1 year ago

Lexaria’s Registered GLP-1 Study #4 Begins Dosing

Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024…

1 year ago

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indicationsThe import was conducted…

1 year ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company’s Pipeline Development

MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing…

1 year ago

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

FREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative…

1 year ago

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable…

1 year ago

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

If approved, UX111 would be the first approved therapy in the U.S. for Sanfilippo Syndrome Type ANOVATO, Calif., Dec. 19,…

1 year ago

Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical…

1 year ago